|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Artinyan A, Mailey B, Sanchez-Luege N,
Khalili J, Sun CL, Bhatia S, Wagman LD, Nissen N, Colquhoun SD and
Kim J: Race, ethnicity, and socioeconomic status influence the
survival of patients with hepatocellular carcinoma in the United
States. Cancer. 116:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Antoni MH, Lutgendorf SK, Cole SW, Dhabhar
FS, Sephton SE, McDonald PG, Stefanek M and Sood AK: The influence
of bio-behavioural factors on tumour biology: Pathways and
mechanisms. Nat Rev Cancer. 6:240–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thaker PH, Han LY, Kamat AA, Arevalo JM,
Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori
M, et al: Chronic stress promotes tumor growth and angiogenesis in
a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cherezov V, Rosenbaum DM, Hanson MA,
Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI,
Kobilka BK and Stevens RC: High-resolution crystal structure of an
engineered human beta2-adrenergic G protein-coupled receptor.
Science. 318:1258–1265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hara MR, Kovacs JJ, Whalen EJ, Rajagopal
S, Strachan RT, Grant W, Towers AJ, Williams B, Lam CM, Xiao K, et
al: A stress response pathway regulates DNA damage through
β2-adrenoreceptors and β-arrestin-1. Nature. 477:349–353. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Quốc Lu'o'ng KV and Nguyễn LT: The roles
of beta-adrenergic receptors in tumorigenesis and the possible use
of beta-adrenergic blockers for cancer treatment: Possible genetic
and cell-signaling mechanisms. Cancer Manag Res. 4:431–445.
2012.PubMed/NCBI
|
|
9
|
Cole SW and Sood AK: Molecular pathways:
Beta-adrenergic signaling in cancer. Clin Cancer Res. 18:1201–1206.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barron TI, Connolly RM, Sharp L, Bennett K
and Visvanathan K: Beta blockers and breast cancer mortality: A
population-based study. J Clin Oncol. 29:2635–2644. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melhem-Bertrandt A, Chavez-Macgregor M,
Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD,
Hortobagyi GN and Gonzalez-Angulo AM: Beta-blocker use is
associated with improved relapse-free survival in patients with
triple-negative breast cancer. J Clin Oncol. 29:2645–2652. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang
F and Wu E: β2-adrenoceptor blocker synergizes with gemcitabine to
inhibit the proliferation of pancreatic cancer cells via apoptosis
induction. Eur J Pharmacol. 665:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kassahun WT, Guenl B, Ungemach FR, Jonas S
and Abraham G: Expression and functional coupling of liver
β2-adrenoceptors in the human hepatocellular carcinoma.
Pharmacology. 89:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katritch V, Cherezov V and Stevens RC:
Structure-function of the G protein-coupled receptor superfamily.
Annu Rev Pharmacol Toxicol. 53:531–556. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pérez-Sayáns M, Somoza-Martin JM,
Barros-Angueira F, Diz PG, Gándara Rey JM and García-García A:
Beta-adrenergic receptors in cancer: Therapeutic implications.
Oncol Res. 19:45–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weddle DL, Tithoff P, Williams M and
Schuller HM: Beta-adrenergic growth regulation of human cancer cell
lines derived from pancreatic ductal carcinomas. Carcinogenesis.
22:473–479. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang D, Ma QY, Hu HT and Zhang M:
β2-adrenergic antagonists suppress pancreatic cancer cell invasion
by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther. 10:19–29.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pérez Piñero C, Bruzzone A, Sarappa MG,
Castillo LF and Lüthy IA: Involvement of α2- and β2-adrenoceptors
on breast cancer cell proliferation and tumour growth regulation.
Br J Pharmacol. 166:721–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toll L, Jimenez L, Waleh N, Jozwiak K, Woo
AY, Xiao RP, Bernier M and Wainer IW: {Beta}2-adrenergic receptor
agonists inhibit the proliferation of 1321N1 astrocytoma cells. J
Pharmacol Exp Ther. 336:524–532. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang D, Ma Q, Wang Z, Zhang M, Guo K,
Wang F and Wu E: β2-adrenoceptor blockage induces G1/S phase arrest
and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway.
Mol Cancer. 10:1462011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liao X, Che X, Zhao W, Zhang D, Bi T and
Wang G: The β-adrenoceptor antagonist, propranolol, induces human
gastric cancer cell apoptosis and cell cycle arrest via inhibiting
nuclear factor κB signaling. Oncol Rep. 24:1669–1676.
2010.PubMed/NCBI
|
|
23
|
Schuller HM: Mechanisms of smoking-related
lung and pancreatic adenocarcinoma development. Nat Rev Cancer.
2:455–463. 2002. View
Article : Google Scholar : PubMed/NCBI
|
